it is put on behalf of sanofi that the assessment of damages would be difficult, if not impossible, for reasons spelled out in detail with some force.
as i am the docket judge, i will not say more about the issues which will fall for determination on the final hearing than is necessary to explain my reasons for coming to the view that an interlocutory injunction should be granted.
9 however, in my opinion, the combination of the longstanding existence and exploitation of the patent in suit together with the failure of genrx to bring revocation proceedings in a timely fashion are factors pointing to the appropriateness of the grant of an injunction.